Abstract:The pan‐cancer analyses of bromodomain containing 9 (BRD9) provided a comprehensive perspective for the development of BRD9‐based targeted therapies for a variety of different cancers. BRD9 may affect cancer progression through different phosphorylation sites or N6‐methyladenosine site modifications. BRD9 could be used as a novel biomarker for diagnosis of multiple cancer types. Our functional study of BRD9 showed interaction with SMARCD1. Knockdown of BRD9 could inhibit the progression of lung and colon cancers through the Wnt/β‐catenin signalling pathway. Background Mutations in one or more genes responsible for encoding subunits within the SWItch/Sucrose Non‐Fermentable (SWI/SNF) chromatin‐remodelling complexes are found in approximately 25% of cancer patients. Bromodomain containing 9 (BRD9) is a more recently identified protein coding gene, which can encode SWI/SNF chromatin‐remodelling complexes subunits. Although initial evaluations of the potential of BRD9‐based targeted therapy have been explored in the clinical application of a small number of cancer types, more detailed study of the diagnostic and prognostic potential, as well as the detailed biological mechanism of BRD9 remains unreported. Methods We used various bioinformatics tools to generate a comprehensive, pan‐cancer analyses of BRD9 expression in multiple disease types described in The Cancer Genome Atlas (TCGA). Experimental validation was conducted in tissue microarrays and cell lines derived from lung and colon cancers. Results Our study revealed that BRD9 exhibited elevated expression in a wide range of tumours. Analysis of survival data and DNA methylation for BRD9 indicated distinct conclusions for multiple tumours. mRNA splicing and molecular binding were involved in the functional mechanism of BRD9. BRD9 may affect cancer progression through different phosphorylation sites or N6‐methyladenosine site modifications. BRD9 could potentially serve as a novel biomarker for diagnosing different cancer types, especially could accurately forecast the prognosis of melanoma patients receiving anti‐programmed cell death 1 immunotherapy. BRD9 has the potential to serve as a therapeutic target, when pairing with etoposide in patients with melanoma. The BRD9/SMARCD1 axis exhibited promising discriminative performance in forecasting the prognosis of patients afflicted with liver hepatocellular carcinoma (LIHC) and mesothelioma. Additionally, this axis appears to potentially influence the immune response in LIHC by regulating the programmed death‐ligand 1 immune checkpoint. For experimental validation, high expression levels of BRD9 were observed in tumour tissue samples from both lung and colon cancer patients. Knocking down BRD9 led to the inhibition of lung and colon cancer development, likely via the Wnt/β‐catenin signalling pathway. Conclusions These pan‐cancer study revealed the diagnostic and prognostic potential, along with the biological mechanism of BRD9 as a novel therapeutic target in human tumours.

Effects of Bromodomain on Subcellular Localization of BRD7

Tumor suppressor bromodomain-containing protein 7 cooperates with Smads to promote transforming growth factor-β responses

BRD7 Suppresses Tumor Chemosensitivity to CHK1 Inhibitors by Inhibiting USP1-mediated Deubiquitination of CHK1

Effect of the RUNX2 Gene Mutations on Subnuclear Localization of the RUNX2 Protein Mutants

Interaction and Functional Research of BRD7 and Adaptor-Related Protein Complex 3δ Protein

Inactivation of BRD7 results in impaired cognitive behavior and reduced synaptic plasticity of the medial prefrontal cortex

BRD7 Stabilizes P53 via Dephosphorylation of MDM2 to Inhibit Tumor Growth in Breast Cancer Harboring Wild-type P53

BRD4 phosphorylation regulates the structure of chromatin nanodomains

Prognostic Relevance of BRD7 Expression in Colorectal Carcinoma

Targeting bromodomian-containing protein 8 (BRD8): An advanced tool to interrogate BRD8

BRD7 Promotes Cell Proliferation and Tumor Growth Through Stabilization of c-Myc in Colorectal Cancer

BRD7 Regulates Cellular Senescence and Apoptosis in ALS by Modulating P21 Expression and P53 Mitochondrial Translocation Respectively

Expression and Localization of FRMD7 in Human Fetal Brain, and a Role for F-actin.

Pan‐cancer analyses of bromodomain containing 9 as a novel therapeutic target reveals its diagnostic, prognostic potential and biological mechanism in human tumours

Cancer-associated polybromo-1 bromodomain 4 missense variants variably impact bromodomain ligand binding and cell growth suppression

Ferm Domain Containing Protein 7 (frmd7) Upregulates the Expression of Neuronal Cytoskeletal Proteins and Promotes Neurite Outgrowth in Neuro-2a Cells

Bromodomain-containing proteins BRD1, BRD2, and BRD13 are core subunits of SWI/SNF complexes and vital for their genomic targeting in <i>Arabidopsis</i>

Unveiling Allosteric Regulation and Binding Mechanism of BRD9 through Molecular Dynamics Simulations and Markov Modeling

BRD3 and BRD4 BET Bromodomain Proteins Differentially Regulate Skeletal Myogenesis

"Dna Binding Region" of Brca1 Affects Genetic Stability Through Modulating the Intra-S-Phase Checkpoint

Bromodomain-containing protein 9 activates proliferation and epithelial-mesenchymal transition of colorectal cancer via the estrogen pathway in vivo and in vitro